Enzalutamide (marketed as Xtandi and formerly known as MDV3100) is an androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of metastatic castration-resistant prostate cancer.
Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine. Early preclinical studies also suggest that enzalutamide inhibits breast cancer cell growth. In August 2012, the U.S. Food and Drug Administration approved enzalutamide for the treatment of castration-resistant prostate cancer.
Xtandi could save thousands of lives
The wonder drug for fighting prostate cancer has been given the green light for use on the NHS .
The National Institute for Health and Care Excellence said enzalutamide should be offered to men in whom the disease has spread to other parts of the body.
Prostate cancer patients’ charity Tackle said: “This offers a vital lifeline to thousands of men facing death sentences due to the limited options for treatment if chemotherapy has failed.”
Previous draft guidance sparked an outcry when Nice said it should be recommended, but stipulated patients could take it only if they had not previously used the drug abiraterone.
The condition was cut from the final guidance document published today.
Watch The Video-